Is the progression rate in Parkinson's disease patients treated with alfa-Dihydroergocryptine monotherapy different from those treated with Levodopa monotherapy

Abstract

alfa-Dihydroergocryptine monotherapy, Levodopa monotherapy, Parkinsonian patients